Carvedilol and vesnarinone: New antiarrhythmic approach in heart failure therapy

Acta Pharmacologica Sinica

Volumn 22, Issue 3, 2001, Pages 193-200

  Cheng, J H ^a   Kamiya, K ^a   Kodama, I ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Action potentials; Antiarrhythmic agents; Carvedilol; Congestive heart failure; Vesnarinone

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ALMOKALANT; AMIODARONE; CALCIUM ION; CARVEDILOL; DOFETILIDE; PIPERANOMETOZINE; POTASSIUM ION; SODIUM CHANNEL BLOCKING AGENT; ANTI ARRHYTHMIA AGENTS; ANTIARRHYTHMIC AGENT; CALCIUM CHANNELS, L TYPE; CARBAZOLE DERIVATIVE; CARDIOTONIC AGENT; PROPANOLAMINE DERIVATIVE; QUINOLINE DERIVATIVE;

ACTION POTENTIAL; CALCIUM CURRENT; CONGESTIVE HEART FAILURE; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; ELECTRIC POTENTIAL; ELECTROCARDIOGRAM; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; NONHUMAN; POTASSIUM CURRENT; REVIEW; ANIMAL; CALCIUM CHANNEL L TYPE; PATHOPHYSIOLOGY; POTASSIUM CHANNEL;

ACTION POTENTIALS; ANIMAL; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNELS, L-TYPE; CARBAZOLES; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMAN; POTASSIUM CHANNELS; PROPANOLAMINES; QUINOLINES; SUPPORT, NON-U.S. GOV'T;

EID: 0035101176     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
2. Randomized trial of losartan versus captopril in patients with over 65 with heart failure
3. Effects of vesnarinone on morbidity and mortality in patients with heart failure: Vesnarinone study group
4. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
5. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
6. + current
7. 2+ current in rabbit ventricular myocytes
8. Ventricular arrhythmias in severe heart failure: Incidence, significance, and effectiveness of antiarrhythmic therapy
9. Arrhythmias and mortality in congestive heart failure
10. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA cooperative studies group
11. Sudden unexpected death in patients with congestiv heart failure: A second frontier
12. Why patients with congestive heart failure die: Arrhythmias and sudden cardiac death
13. Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction
14. Antiarrhythmic drugs
15. Preliminary report: Effects of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
16. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence
17. Emerging class III antiarrhythmic agents: Mechanisms of action and proarrhyttmic potential
18. Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm
19. Cellular electropharmacology of amiodarone
20. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent
21. Barium-induced non-driven action potentials as a model of triggered potentials from early afterdepolarization: Significance of slow-channel activity and differing effects of quinidine and amiodarone
22. Amiodarone-associated proarrhyttmic effects: A review with special reference to torsades de pointes tachycardia
23. Carvedilol: A review of its pharmacological and pharmacokinetic properties, and therapeutic efficacy
24. Carvedilol: A reappraisal of its pharmacological properties and therapeutical use in cardiovascular disorders
25. Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs
26. Antiarrhythmic effects of carvedilol in rat isolated heart subjected to ischemia and reperfusion
27. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury
28. + current in rabbit ventricular myocytes
29. Adrenergic nervous system in heart failure
30. Effects of carvedilol on ventricular arrhythmias
31. Intractable recurrent ventricular tachycardia in dilated cardiomyopathy controlled by a vasodilating β blocker
32. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial
33. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
34. Membrane current changes responsible for the positive inotropic effects of OPC 8212, a new positive inotropic agent, in single ventricular cells of guinea pig heart
35. Ionic basis for OPC-8212-induced increase in action potential duration in isolated rabbit, guinea pig and human ventricular myocytes
36. + current: A potential mechanism of the proarrhythmic effects of methanesulfonanilide class III agents
37. + current in cardiac myocytes by dofetilide
38. + current by almokalant in rabbit ventricular myocytes
39. Cellular electrophysiology in cardiac hypertrophy and failure
40. Potassium channel down-regulation in heart failure
41. Cardiac hypertrophy, arrhyttmogenicity and the new myocardial phenotype. II. The cellular adaptional process
42. + currents in dogs with chronic complete atrioventricular block and acquired Torsades de Pointes